Incidence Rates of Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Arthritis Treated with TNFi Agents and DMARDs

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104

Support: This project was supported by the Children's Hospital of Philadelphia Author degrees and affiliations: K. Baggett, BS, Department of Pediatrics, Division of Rheumatology; T.G. Brandon, MPH, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; R. Xiao, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania; Z. Valenzuela, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia; L.H. Buckley, MD, MSHP, Department of Pediatrics, Division of Rheumatology, Monroe Carell Jr. Children's Hospital at Vanderbilt; P.F. Weiss, MD, MSCE, Department of Pediatrics, Division of Rheumatology and Center for Pediatric Clinical Effectiveness at the Children's Hospital of Philadelphia and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Conflict of interest: Dr. Weiss has served as a consultant for Lilly, Biogen, Pfizer, and Novartis. Corresponding Author: Pamela F. Weiss, MD, MSCE, The Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 11121, Philadelphia PA 19104